Want to see MDT full AI Analyst Report?
Revenue by Segment
Sales split by Medtronic’s business units and product lines, showing which therapies (e.g., cardiac, minimally invasive, spine, surgical) drive growth and profitability. Helps investors judge whether growth is broad-based or concentrated, which segments carry regulatory or competitive risks, and where margin expansion or contraction is likely.
Cardiovascular and Diabetes are the primary growth engines: cardiovascular has meaningfully re-accelerated, reflecting CAS and renal denervation momentum, while Diabetes posts steady, compounding gains even as Medtronic plans the MiniMed separation. Medical surgery and neuroscience show steady progress with robotics and neuromodulation as upside but lag the cardiovascular cadence. Management’s FY‑27 guidance (mid‑single‑digit organic growth with a Q1 selling‑week boost and modest inorganic lift) underpins continued top‑line momentum, though tariffs, transport costs and increased R&D/SG&A will constrain near‑term margin tailwinds.
MDT Revenue by Segment
| Date | Other | Cardiovascular | Medical Surgery | Neuroscience | Diabetes |
|---|---|---|---|---|---|
| Jun 30, 2026 | $29.00M | $3.93B | $2.68B | $2.28B | $843.00M |
| Mar 31, 2026 | $34.00M | $3.80B | $2.39B | $2.75B | $837.00M |
| Dec 31, 2025 | $32.00M | $3.46B | $2.17B | $2.56B | $796.00M |
| Sep 30, 2025 | $35.00M | $3.44B | $2.17B | $2.56B | $757.00M |
| Jun 30, 2025 | $73.00M | $3.29B | $2.08B | $2.42B | $721.00M |
| Mar 31, 2025 | $31.00M | $3.34B | $2.21B | $2.62B | $728.00M |
| Dec 31, 2024 | $32.00M | $3.04B | $2.07B | $2.46B | $694.00M |
| Sep 30, 2024 | $37.00M | $3.10B | $2.13B | $2.45B | $686.00M |
| Jun 30, 2024 | -$52.00M | $3.01B | $2.00B | $2.32B | $647.00M |
| Mar 31, 2024 | $57.00M | $3.13B | $2.20B | $2.54B | $660.00M |
| Dec 31, 2023 | $17.00M | $2.93B | $2.15B | $2.35B | $640.00M |
| Sep 30, 2023 | $22.00M | $2.92B | $2.14B | $2.29B | $610.00M |
| Jun 30, 2023 | $16.00M | $2.85B | $2.04B | $2.22B | $578.00M |
| Mar 31, 2023 | $0.00 | $3.30B | $2.12B | $2.41B | $595.00M |
| Dec 31, 2022 | $0.00 | $2.77B | $2.14B | $2.25B | $570.00M |
| Sep 30, 2022 | $0.00 | $2.77B | $2.07B | $2.19B | $556.00M |
| Jun 30, 2022 | $0.00 | $2.71B | $2.00B | $2.12B | $541.00M |
| Mar 31, 2022 | $0.00 | $2.96B | $2.23B | $2.30B | $597.00M |
| Dec 31, 2021 | $0.00 | $2.75B | $2.29B | $2.14B | $584.00M |
| Sep 30, 2021 | $0.00 | $2.83B | $2.30B | $2.14B | $585.00M |
| Jun 30, 2021 | $0.00 | $2.89B | $2.32B | $2.20B | $572.00M |
| Mar 31, 2021 | $0.00 | $2.91B | $2.34B | $2.29B | $647.00M |
| Dec 31, 2020 | $0.00 | $2.71B | $2.31B | $2.13B | $630.00M |
| Sep 30, 2020 | $0.00 | $2.73B | $2.29B | $2.06B | $574.00M |
| Jun 30, 2020 | $0.00 | $2.43B | $1.80B | $1.71B | $562.00M |
| Mar 31, 2020 | $0.00 | $2.00B | $1.93B | $1.49B | $570.00M |